目的 比较佐米曲普坦片和盐酸洛美利嗪胶囊治疗偏头痛的临床疗效。方法 选取2013年1月—2014年10月滨州医学院烟台附属医院神经内科门诊收治的偏头痛患者110例,随机分为对照组和治疗组,每组各55例。对照组早晚饭后口服盐酸洛美利嗪胶囊,5 mg/次,2次/d。治疗组患者口服佐米曲普坦片,2.5 mg/次,1次/d。两组均连续治疗4周。观察两组的临床疗效,同时比较两组治疗前后视觉模拟(VAS)评分、头痛发作频率、24 h内头痛缓解维持时间的变化。结果 治疗后,对照组和治疗组的总有效率分别为76.36%、94.55%,两组比较差异具有统计学意义(P <0.05)。治疗后,两组患者VAS评分、患者头痛发作频率均较治疗前显著降低,24 h内头痛缓解维持时间均显著提高,同组治疗前后差异具有统计学意义(P <0.05);且治疗组这些观察指标的改善程度优于对照组,两组比较差异具有统计学意义(P <0.05)。随访4周,对照组和治疗组的复发率分别为14.55%、5.45%,两组比较差异具有统计学意义(P <0.05)。结论 佐米曲普坦片治疗偏头痛疗效显著,且复发率较低,安全性高,有较好的应用和推广价值。

Objective To compare the clinical effect of Zolmitriptan Tablets and Lomerizine Hydrochloride Capsules in treatment of migraine. MethodsPatients (110 cases) with migraine in Department of Neurology outpatient service of Yantai Affiliated Hospital of Binzhou Medical University from January 2013 to October 2014 were randomly divided into control and treatment groups, and each group had 55 cases. The patients in the control group were po administered with Lomerizine Hydrochloride Capsules after breakfast and dinner, 5 mg/time, twice daily. The patients in the treatment group were po administered with Zolmitriptan Tablets, 2.5 mg/time, once daily. Two groups were treated for four weeks. After treatment, the efficacy was evaluated, and the changes of VAS score, headache frequency, headache relief to maintain time within 24 h in two groups before and after treatment were compared. Results After treatment, the efficacies in the control and treatment groups were 76.36% and 94.55%, respectively, and there was difference between two groups (P < 0.05). After treatment, VAS score and headache frequency in two groups were significantly reduced, and headache relief to maintain time within 24 h was significantly increased, and the difference was statistically significant in the same group (P < 0.05). And these indicators in treatment group improved better than those in the control group, with significant differences between two groups (P < 0.05). Followed up for four weeks, the recurrence rate in the control and treatment groups were 14.55% and 5.45%, respectively, and there was difference between two groups (P < 0.05). Conclusion Zolmitriptan Tablets has obvious therapeutic effect in treatment of migraine with low recurrence rate and high safety, which has the good application and promotion value.